参　考　文　献[1]叶志中,许香广,等.霉酚酸酯治疗重症系统性红斑狼疮的临床研究[J].中华风湿病学杂志,2001,5:313-316[2]OngLM,HooiLS.Randomizedcontrolledtralofpulseintravenouscyclophosphamideversusmycophenolatemofetilintheinductiontherapyofproliferativelupusnephritis[J].Nephrology（Carlton）,2005,10（5）:504-510[3]ChowKM,SzetoCC.Leflunomideandanti-glomerularbasementmem-braneglomerulonephritis:commentontheletterbyBruyn[J].ArthritisRheum,2004,50（1）:336-337.[4]TamLS,LiEK,WongCK,etal.Safetyandefficacyofleflunomideinthetreatmentoflupusnephritisrefractoryorintoleranttotraditionalimmunosuppressivetherapy:anopenlabeltrial[J].AnnRheumDis,2006,65（3）:417-418.[5]LooneyRJ,AnolikJH,CampbellD,etal.Bcelldepletionasanoveltreatmentforsystemiclupuserythematosus:aphaseI/IIdose-escalationtrialofrituximab[J].ArthritisRheum,2004,50:2580-2589.[6]SfikakisPP,BoletisJN,LionakiS,etalRemissionofproliferativelupusnephritisfollowingBcelldepletiontherapyisprecededbydown-regulationoftheTcellcostimulatorymoleculeCD40ligand:anopen-labeltrial[J].ArthritisRheum.2005,52（2）:501-513.[7]SmithKG,JonesRB,BurnsSM,etal.Long-termcomparisonofrituximabtreatmentforrefractorysystemiclupuserythematosusandvasculitis:Remission,relapse,andre-treatment[J].ArthritisRheum,2006,54（9）:2970-2982[8]Alarcon-SegoviaD,TumlinJA,FurieRA,etal.LJP394forthepreventionofrenalflareinpatientswithsystemiclupuserythematosus[J].ArthritisRheum,2003,48:442-454.[9]BoumpasDT,FurieR,ManziS,etal.AshortcourseofBG9588（antiCD40ligandantibody）improvesserologicactivityanddecreaseshematuriainpatientswithproliferativelupusglomerulonephritis[J].ArthritisRheum,2003,48:719-727.[10]DaikhD,WofsyD.CuttingEdge:reversalofmurinelupusnephritiswithCTLA4Igandcyclophosphamide[J].JImmunol,2001,166:2913-2916.[11]WeinblattM,SchiffM,GoldmanM,etal.ApilotmulticentrerandomiseddoubleblindplacebocontrolledtrialofacostimulatorblockerCTLA4Iggivenmonthlyincombinationwithetanerceptinactiverheumatoidarthritis[J].ArthritisRheum,2002,46:204.[12]SrandV.Monoclonalantibodiesandotherbiologicaltherapies[J].Lupus,2001,10:216-221.[13]LlorenteL,Richaud-PatinY,Garcia-PadillaC,etal.Clinicalandbiologicaleffectsofanti-interleukin10monoclonalantibodyadministrationinsystemiclupuserythematosus[J].ArthritisRheum,2000,43:1790-1800.[14]WangY,HuQ,MadriJA,etal.AmeliorationoflupuslikeautoimmunediseaseinNZB/WF1miceaftertreatmentwithablockingmonoclonalantibodyspecificforcomplementcomponentC5[J].ProcNatlAcadSciUSA,1996,93:8563-8568.[15]RavirajanCT,WangY,MatisLA,etal.EffectofneutralizingantibodiestoIL-10andC5ontherenaldamagecausedbyapathogenichumananti-dsDNAantibody[J].Rheumatology,2004,43:442-447.来源：社区医学杂志作者：邹原方叶志中